Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

AI helps kidney patients discuss future treatment options

NCT ID NCT06056518

Knowledge-focused Sponsor: Charite University, Berlin, Germany Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tested whether an AI tool that predicts the risk of kidney transplant failure within one year can improve conversations between patients, their families, and doctors. 76 adults with a functioning kidney transplant but declining kidney function took part. The goal was to see if the AI helped them make shared decisions about what to do if the transplant eventually fails.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
AI-based risk prediction tool
What this could lead to
If successful, this could show that AI helps patients and doctors make better shared decisions about what to do if a kidney transplant fails.
What could go wrong
This was a small, single-center study that ended early due to high dropout and funding limits. The AI tool only predicts risk and does not directly improve health.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

76 people

The number who actually took part.

Started

Jan 2024

Finished

Oct 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * written informed consent * patients with functioning kidney allograft * \> 12 months after transplantation * eGFR \< 30 ml/min/1.73m2 according to CKD-EPI 2021 formula * at least 18 years of age * ability to communicate in German * regular follow-up at kidney transplant center Exclusion Criteria: * multi-organ transplantation * eGFR \> 30 ml/min/1.73m2 according to CKD-EPI 2021 formula * \<= 12 months after transplantation * less than 18 years of age * not able to communicate in German * no regular follow-up at kidney transplant center * enrollment in another interventional study less than 1 month before participation in this study

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Chronic kidney disease stage 4 are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

chronic kidney disease

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Kidney transplant failure

Contacts and locations

Locations

  • Charité - Universitätsmedizin Berlin

    Berlin, State of Berlin, 10117, Germany

More trials for these conditions

Other studies related to the condition(s) this trial covers.